Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents With Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma

Next Previous
Trial Profile

Phase I Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3-Octreotate (177Lu-DOTATATE) in Children and Adolescents With Neuroendocrine Tumor or Pheochromocytoma/Paraganglioma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Neuroblastoma; Neuroendocrine tumours; Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 03 Jun 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 12 Nov 2020 Planned number of patients changed from 74 to 37.
  • 03 Mar 2020 Planned initiation date changed from 1 Jul 2019 to 1 May 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top